Vector Science & Therapeutics Corp., a medical technology and therapeutic delivery company, has announced its first quarterly financial results as a public company. The company is headquartered in Mequon, Wisconsin, and is focused on developing technologies to improve the delivery of pharmaceutical agents, peptides, biologics, and other therapeutic compounds.
Peptide Manufacturing and VectorMist
Vector’s peptide manufacturing operation is scaling up, with first production batches expected in August 2026 and initial revenue anticipated before the company’s fiscal quarter end in August. The company has signed agreements with leading athletes to serve as product spokespeople as part of its pre-launch marketing program. VectorMist, the company’s perioperative pain management technology for laparoscopic surgery, remains on track for submission to the FDA for 510(k) clearance.
The company is also hosting its inaugural investor Q&A on July 28, 2026, via Microsoft Teams. The Q&A will provide an opportunity for investors to ask questions and learn more about the company’s progress and future plans.
Original reporting: KTBS 3 (Shreveport) — read the source article.
